S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$3.99
-0.10 (-2.44%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.90
$4.10
50-Day Range
$3.99
$5.12
52-Week Range
$3.90
$11.23
Volume
398,520 shs
Average Volume
264,930 shs
Market Capitalization
$194.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.48
30 days | 90 days | 365 days | Advanced Chart
Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Paratek Pharmaceuticals logo

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Headlines

Options Play of the Week: Paratek Pharmaceuticals
December 5, 2021 |  finance.yahoo.com
Recap: Paratek Pharmaceuticals Q3 Earnings
November 8, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
197
Year Founded
1996

Sales & Book Value

Annual Sales
$46.92 million
Book Value
($2.24) per share

Profitability

Net Income
$-96.54 million
Pretax Margin
-45.32%

Debt

Price-To-Earnings

Miscellaneous

Free Float
46,306,000
Market Cap
$194.69 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/21/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

553rd out of 1,418 stocks

Pharmaceutical Preparations Industry

262nd out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view top-rated stocks.

How has Paratek Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 2.6% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19
.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Paratek Pharmaceuticals
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share.
View Paratek Pharmaceuticals' earnings history
.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $128 million-$139 million, compared to the consensus revenue estimate of $135.17 million.

What price target have analysts set for PRTK?

4 brokerages have issued 12 month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 313.5% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Evan Loh, Chief Executive Officer & Director (LinkedIn Profile)
  • Adam Woodrow, President & Chief Commercial Officer (LinkedIn Profile)
  • Sarah Higgins, VP, Chief Financial & Accounting Officer
  • Raj Padmanabhan, Vice President-Information Technology
  • Paul McGovern, Vice President-Clinical & Medical Affairs

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $3.99.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $194.69 million and generates $46.92 million in revenue each year. The specialty pharmaceutical company earns $-96.54 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 197 workers across the globe.

When was Paratek Pharmaceuticals founded?

Paratek Pharmaceuticals was founded in 1996.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at [email protected], or via fax at 617-275-0039.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.